Determinants of Survival of Cervical Cancer: A Hospital Based StudyRita Rani*, Usha Singh, Vinita Trivedi, Richa Chauhan and Abha Kumari
Department of Radiotherapy, Mahavir Cancer Institute and research Centre, Patna, India
- *Corresponding Author:
- Rita Rani
Department of Radiotherapy
Mahavir Cancer Institute and research Centre
Tel: 070914 90890
E-mail: [email protected]
Received date: April 8, 2017; Accepted date: May 8, 2017; Published date: May 15, 2017
Citation: Rita R, Singh U, Trivedi V, Chauhan R, Kumari A (2017) Determinants of Survival of Cervical Cancer: A Hospital Based Study. Gynecol Obstet 7:437. doi:10.4172/2161-0932.1000437
Copyright: © 2017 Rani R, et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Globally uterine cervix cancer is one of the leading causes of death in females due to cancer, especially in developing countries. The aim of the study was to analyse the survival as well as understanding various prognostic factors for survival in patients of carcinoma cervix presenting in our hospital. A total of 508 patients were evaluated in radiotherapy department of Mahavir Cancer Sansthan and Research centre Patna, Bihar who came for follow up between April 2015 to March 2016 after completion of radical radiotherapy. Out of 508 patients 3.54% (n 18), 71.65% (n 364), 22.83% (n 116) and 1.9% (n 10) patients presented in sage I, II, III and IV A respectively. 53.54% of patients belonged to age group of 35 to 50 years with Survival of 937 ± 53.49 days. 46.46% of the patients were more than 50 years age and their survival was 933.3 ± 57.12 days. The mean duration for overall survival for all cases evaluated was 957.4 ± 39.49 days. The mean duration for survival of stages I, II, III and IVA was 1186 ± 281.8 days, 960 ± 85.04 days, 945.1 ± 45.66 days and 765 ± 181.5 days respectively. Survival of patients having squamous cell carcinoma was 970 ± 42.89 days and that of adenocarcinoma was 669.5 ± 120 days and that of premenopausal and postmenopausal lady was 997.5 ± 79.28 and 940.1 ± 45.39 days respectively. It was evident from study that patients who presented in early stage had a better survival. There was no significant difference in survival of cervix cancer patients in different age groups while survival was greater in premenopausal cervical cancer patients.